EVALUATION OF THE EFFICIENCY AND SAFETY OF LIPID-LOWERING THERAPY IN COMORBID PATIENTS

DOI: https://doi.org/10.29296/25877305-2018-04-10
Download full text PDF
Issue: 
4
Year: 
2018

V. Shishkova, Candidate of Medical Sciences; A. Remennik, Candidate of Medical Sciences; L. Zotova; E. Zotova Center for Speech Pathology and Neurorehabilitation, Moscow

The efficacy and safety of pitavastatin at doses of 2 and 4 mg daily and rosuvastatin at a dose of 10 mg daily were investigated in comorbid patients with first-time ischemic stroke.
Keywords: 
cardiology
neurology
ischemic stroke
comorbid patients
lipid-lowering therapy
pitavastatin

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Shal'nova S.A., Deev A.D. Tendentsii smertnosti v Rossii v nachale XXI veka (po dannym ofitsial'noj statistiki) // Kardiovask. ter. i profilakt. – 2011; 10 (6): 5–10.
  2. Oganov R.G., Maslennikova G.Ja. Demograficheskie tendentsii v Rossijskoj Federatsii: vklad boleznej sistemy krovoobraschenija // Kardiovask. ter. i profilakt. – 2012; 11 (2): 5–10.
  3. Rekomendatsii EOK/EOA po diagnostike i lecheniju dislipidemij 2016 // Ros. kardiol. zhurn. – 2017; 5 (145): 7–77.
  4. Barylski M., Nikolic D., Banach M. et al. Statins and New-Onset Diabetes // Current Pharmaceutical Design. – 2013; 19: 1–8.
  5. Sattar N., Preiss D., Murray H. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials // Lancet. – 2010; 375: 735–42.
  6. Ishikawa M., Okajima F., Inoue N. et al. Distinct effects of pravastatin, atorvastatin and simvastatin on insulin secretion from a beta-cell line, MIN6 cells // J. Atheroscler. Thromb. – 2006; 13 (6): 329–35.
  7. Yamakasava T., Takano T., Tanaka S. et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus // J. Atheroscler. Thromb. – 2008; 15: 269–75.
  8. Boyd C. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for performance // JAMA. – 2005; 294 (6): 716–24.
  9. Shishkova V.N. Komorbidnost' i polipragmazija // Vrach. – 2017; 7: 26–30.
  10. Mukhtar R., Reid J., Reckless J. Pitavastatin // Int. J. Clin. Pract. – 2005; 59: 239–52.
  11. Weng T., Yang Y., Lin S. et al. A systematic review and meta-analysis on the therapeutic equivalence of statins // J. Clin. Pharm. Ther. – 2010; 35: 139–51.
  12. da Silva P. Are all statins the same?: Focus on the efficacy and tolerability of pitavastatin // Am. J. Cardiovasc. Drug. – 2011; 11: 93–107.
  13. Corsini A., Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins ’Achilles’ heel? // Curr. Med. Res. Opin. – 2011; 27: 1551–62.
  14. Kurihara Y., Douzono T., Kawakita K. et al. A large-scale, long-term, prospective postmarketing surveillance olpitavastatin (LIVALO® Tablet) – LIVALO Effectiveness and Safety (LIVES) Study // Jpn. Pharmacol. Ther. – 2008; 36: 709–31.
  15. Shishkova V.N., Kapustina L.A. Problemy komorbidnogo patsienta: kak vybrat' pravil'nyj statin // Farmakoterapija. – 2017; 17: 14–23.
  16. Takayama K., Taki W., Toma N. et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study – EPOCH-CAS Study // Cardiovasc. Intervent. Radiol. – 2014; 37: 1436–43.
  17. Katapano A., Kuharchuk V.V., Sergienko I.V. i dr. Pitavastatin – sovremennyj statin dlja korrektsii dislipidemii i riska serdechno-sosudistyh oslozhnenij. Rezoljutsija ekspertnogo soveta // Ateroskleroz i dislipidemii. – 2017; 2: 104–6.